Renalytix PLC
LSE:RENX

Watchlist Manager
Renalytix PLC Logo
Renalytix PLC
LSE:RENX
Watchlist
Price: 6.25 GBX Market Closed
Market Cap: 27.3m GBX

Renalytix PLC
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Renalytix PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Renalytix PLC
LSE:RENX
Revenue
$2.3m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Craneware PLC
LSE:CRW
Revenue
$205.7m
CAGR 3-Years
8%
CAGR 5-Years
24%
CAGR 10-Years
16%
Cambridge Cognition Holdings PLC
LSE:COG
Revenue
£9.1m
CAGR 3-Years
-8%
CAGR 5-Years
9%
CAGR 10-Years
4%
Feedback PLC
LSE:FDBK
Revenue
£885.6k
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
9%
Doctor Care Anywhere Group PLC
ASX:DOC
Revenue
£39.3m
CAGR 3-Years
16%
CAGR 5-Years
47%
CAGR 10-Years
N/A
P
Physitrack PLC
STO:PTRK
Revenue
€16.2m
CAGR 3-Years
24%
CAGR 5-Years
68%
CAGR 10-Years
N/A
No Stocks Found

Renalytix PLC
Glance View

Market Cap
27.3m GBX
Industry
Health Care

Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.

RENX Intrinsic Value
0.61 GBX
Overvaluation 90%
Intrinsic Value
Price

See Also

What is Renalytix PLC's Revenue?
Revenue
2.3m USD

Based on the financial report for Jun 30, 2024, Renalytix PLC's Revenue amounts to 2.3m USD.

What is Renalytix PLC's Revenue growth rate?
Revenue CAGR 3Y
15%

Over the last year, the Revenue growth was -33%. The average annual Revenue growth rates for Renalytix PLC have been 15% over the past three years .

Back to Top